Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528881 | 0.89 | KMT2A (0.43) | MRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4432869 | 0.84 | MRGPRX4 (0.59) | MRGPRX4MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4425188 | 0.84 | MRGPRX4 (0.51) | MRGPRX4MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL5807943 | 0.81 | MAOB (0.51) | MRGPRX4MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4424330 | 0.80 | MRGPRX4 (0.52) | MRGPRX4GRM5MAOBGAAKDM4E | |
| SCHEMBL4425971 | 0.79 | MRGPRX4 (0.58) | MRGPRX4GRM5MAOBNPC1RAB9A | |
| SCHEMBL22386723 | 0.78 | MAOB (0.54) | MRGPRX4GRM5MAOBNR4A2PARP10 | |
| SCHEMBL92218 | 0.78 | MTNR1A (0.52) | SMN1; SMN2 | |
| SCHEMBL20463366 | 0.77 | MAOB (0.69) | MRGPRX4MAOBNR4A2PARP10 | |
| SCHEMBL67796 | 0.76 | MAOB (0.54) | MRGPRX4GRM5MAOBNR4A2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515926-B1 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-6951884-B2 | Fluorobenzamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1515926-A2 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | F.HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20030236304-A1 | Fluorobenzamides and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-25 | — | — | US | disclosed |
| WO-2003106380-A2 | FLUOROBENZAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236304-A1 | Fluorobenzamides and uses thereof | MAOB, MAOA, BCHE | MRGPRX4 1009/4885GRM5 1316/4885MAOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.